Alkermes (ALKS) EPS (Diluted) (QoQ) (2010 - 2026)
Powered by 
Analysis
Alkermes (ALKS) EPS (Diluted) (QoQ) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 644.32 Bn | 623.56 Bn | 17.26 Bn |
| 2 | AbbVie | 440.60 Bn | 434.04 Bn | 12.70 Bn |
| 3 | Merck | 365.39 Bn | 358.25 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.73 Bn | 259.04 Bn | 11.24 Bn |
| 5 | Pfizer | 159.22 Bn | 147.52 Bn | 10.94 Bn |
| 6 | Sanofi | 52.48 Bn | 45.10 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.21 Bn | 44.21 Bn | - |
| 8 | Incyte | 25.34 Bn | 20.81 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.49 Bn | 18.82 Bn | 683.80 Mn |
| 10 | Alkermes | 7.58 Bn | 6.93 Bn | 397.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 100.75% |
| Mar 31, 2026 | -236.76% |
| Dec 31, 2025 | -40.39% |
| Sep 30, 2025 | -5.08% |
| Jun 30, 2025 | 288.60% |
| Mar 31, 2025 | -84.67% |
| Dec 31, 2024 | 57.08% |
| Sep 30, 2024 | 4.18% |
| Jun 30, 2024 | 152.14% |
| Mar 31, 2024 | -70.16% |
| Dec 31, 2023 | 162.62% |
| Sep 30, 2023 | -80.56% |
| Jun 30, 2023 | 569.59% |
| Mar 31, 2023 | -154.86% |
| Dec 31, 2022 | 237.73% |
| Sep 30, 2022 | -111.71% |
| Jun 30, 2022 | 16.76% |
| Mar 31, 2022 | -128.35% |
| Dec 31, 2021 | 534.12% |
| Sep 30, 2021 | -1,345.07% |